Lipid Profile Alterations in the Metabolic Syndrome The Latest Biochemical and Physiological Aspect

Dr. Ashfaq ul Hassan; Dr. Shazia Nazir

Authors

Dr. Ashfaq ul Hassan
Dr. Shazia Nazir

Keywords:

apolipoproteins, esterfication, syndrome, circumference, waist, glucocorticoids, lipase

Abstract

Cardiovascular and cerebrovacular complications form a major challenge in the management of the The Metabolic Syndrome. The risks of development are compounded by simultaneous occurrence of Type 2 diabetes mellitus (T2DM), dyslipid emias, hypertension and other medical conditions. The significant increase in morbidity, mortality along with premature death and disabilities resulting from these conditions in both developed and developing is a matter of great concern. The article makes a microanalysis of Biochemical alterations associated with dyslipidemias in cases of metabolic syndrome.

Downloads

How to Cite

Lipid Profile Alterations in the Metabolic Syndrome The Latest Biochemical and Physiological Aspect. (2015). Global Journal of Medical Research, 15(19), 19-23. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

Author Biography

Dr. Ashfaq ul Hassan

Dr. Ashfaq Ul Hassan is a medical researcher and academic affiliated with the Sher-i-Kashmir Institute of Medical Sciences (SKIMS) in Srinagar, India. His work spans anatomy, radiology, and neurosurgery, with published case studies on rare conditions such as internal carotid agenesis, median nerve schwannoma, and open lip schizencephaly with agenesis of the corpus callosum. He has also contributed to research on metabolic syndrome and trauma management. With over 85 publications and 216 citations, Dr. Hassan holds an h-index of 7 and an i10-index of 6, reflecting his ongoing impact in the medical field.

References

Eleazar Shafrir (1993) Animal Models of Syndrome X. 12, 165-181.

Lempiainen P (1999) Insulin Resistance Syndrome Predicts Coronary Heart Disease Events in Elderly Nondiabetic Men. 100(2), 123-128.

(2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 285, 2486-2497.

Peter Wilson, Ralph D'agostino, Helen Parise, Lisa Sullivan, James Meigs (2005) Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. 112(20), 3066-3072. https://doi.org/10.1161/circulationaha.105.539528

DJ Nieves, Cnop M, Retzlaff B (2003) The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intraabdominal fat. 52, 2-9.

Robert Ross, Jennifer Freeman, Robert Hudson, Ian Janssen (2002) Abdominal obesity, muscle composition, and insulin resistance in premenopausal women J Clin Endocrinol Metab. 87(11), 5044-5051. https://doi.org/10.1210/jc.2002-020570

Mark Danese, Paul Ladenson, Curtis Meinert, Neil Powe (2000) Effect of Thyroxine Therapy on Serum Lipoproteins in Patients with Mild Thyroid Failure: A Quantitative Review of the Literature*. 85(9), 2993-3001. https://doi.org/10.1210/jcem.85.9.6841

B. Wajchenberg (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome Endocr Rev. 21(6), 697-738. https://doi.org/10.1210/er.21.6.697

Delma Nieves, Miriam Cnop, Barbara Retzlaff, Carolyn Walden, John Brunzell, Robert Knopp, Steven Kahn (2003) The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intraabdominal fat Diabetes. 52(1), 172-179. https://doi.org/10.2337/diabetes.52.1.172

Pascot Lemieux I, Lamarche Couillard C, Tchernof A, Bergeron Alme ras N, Tremblay Gaudet D, Prud (2000) Hypertriglyceridemic Waist. 102, 179-184.

Despres JP, Golay A, Sjostrom L (2005) Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. 353(20), 2121-2134. https://doi.org/10.1056/nejmoa044537

HN Ginsberg, LS Haung (2000) The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis. 7, 3235-3331.

Drayna D, Jamagin AS, Mclean J (1987) cloning and sequencing of the human cholesteryl ester transfer protein cDNA. 327(6123), 6324. https://doi.org/10.1038/327632a0

Morton RE (1999) Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. 10, 321-327.

Arai T, Yamashita S, Hirano K (1994) Increased plasma cholesteryl ester transfer protein in obese subjects: a possible mechanism for the reduction of serum HDL cholesterol levels in obesity. 14, 1129-1136.

C. Packard, T. Watson (1997) Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men. 17, 1454-1464.

Ginsberg HN, Le N-A, Goldberg IJ (1986) Apolipoprotein B metabolism in subjects with deficiency of apoliporoteins C-III and AI; evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. 78, 1287-95.

B. Lamarchc, A. Tchernof, P. Mauriege (1998) Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease. 279, 55-61.

Chatt A, Brazg RL, Tribble DL (1993) Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. 94, 350-356.

Wilson PW, Grundy SM (2003) The metabolic syndrome: practical guide to origins and treatment: part I. 108, 1422-1424.

P. Barter, K-A Rye (1996) High density lipoproteins and coronary heart disease. 121(1), 1-12. https://doi.org/10.1016/0021-9150(95)05675-0